NovoCure Limited
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-136.2M | $-168.6M | $-207.0M | $-92.5M | $-58.4M | $19.8M | $-7.2M | $-63.6M |
| Depreciation & Amortization | $14.7M | $11.2M | $11.0M | $10.6M | $10.3M | $9.2M | $8.5M | $9.0M |
| Depreciation | $9.4M | $6.2M | $3.9M | $3.1M | $2.8M | $2.6M | $2.1M | $2.0M |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $104.8M | $160.0M | $115.6M | $107.0M | $94.9M | $75.7M | $52.4M | $39.8M |
| Net Cash from Operating Activities | $-49.0M | $-26.4M | $-73.3M | $30.8M | $82.8M | $99.1M | $26.6M | $-1.9M |
| Investing Activities | ||||||||
| Capital Expenditures | $26.6M | $42.9M | $27.1M | $21.4M | $24.2M | $15.0M | $10.5M | $6.7M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $437.3M | $-140.2M | $184.1M | $-140.0M | $-144.8M | $-472.8M | $-51.7M | $-5.5M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-451.3M | $90.3M | $15.8M | $15.5M | $25.7M | $440.2M | $61.7M | $69.4M |
| Net Change in Cash | $-62.7M | $-76.5M | $126.7M | $-93.8M | $-36.6M | $66.8M | $36.7M | $62.0M |
| Free Cash Flow | $-75.7M | $-69.2M | $-100.4M | $9.4M | $58.6M | $84.2M | $16.1M | $-8.6M |